Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReLive Study: Doxorubicin Transdrug vs Best Standard of Care in Advanced Hepatocellular Carcinoma After Sorafenib Failure
2011-002843-92Phase 3Completed
- Sponsor
- Valerio Therapeutics
- Start
- Mar 2013
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Livatag in hepatocellular carcinoma (HCC) (3 arms), sponsored by Valerio Therapeutics. Primary endpoint: Overall survival. Started Mar 2013; status: completed.
02
Drugs
Livatag
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2011-002843-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002843-92.